These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 7025341)

  • 21. [Treatment of connective tissue disorder-related acral syndromes using UVA-1 phototherapy. An open study of 11 cases].
    Comte C; Bessis D; Picot E; Peyron JL; Guillot B; Dereure O
    Ann Dermatol Venereol; 2009 Apr; 136(4):323-9. PubMed ID: 19361698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect of prostacyclin on cerebral vasospasm--an experimental study].
    Quintana L; Konda R; Ishibashi Y; Okada H; Suzuki J
    No Shinkei Geka; 1982 Oct; 10(10):1049-52. PubMed ID: 6757779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostaglandin E1 infusions for vascular insufficiency in progressive systemic sclerosis.
    Martin MF; Dowd PM; Ring EF; Cooke ED; Dieppe PA; Kirby JD
    Ann Rheum Dis; 1981 Aug; 40(4):350-4. PubMed ID: 7259326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Diagnostic importance of digital topographic assessment of Raynaud's phenomenon. A prospective study of a population of 522 patients].
    Pistorius MA; Planchon B
    J Mal Vasc; 1995; 20(1):14-20. PubMed ID: 7745354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of Raynaud's phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis.
    Gardinali M; Pozzi MR; Bernareggi M; Montani N; Allevi E; Catena L; Cugno M; Bottasso B; Stabilini R
    J Rheumatol; 2001 Apr; 28(4):786-94. PubMed ID: 11327251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Possibilities for clinical use of prostacyclin in vascular disease.
    Poredos P
    Pflugers Arch; 2000; 440(5 Suppl):R137-8. PubMed ID: 11005643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of severe Raynaud's syndrome by injection of autologous blood pretreated by heating, ozonation and exposure to ultraviolet light (H-O-U) therapy.
    Cooke ED; Pockley AG; Tucker AT; Kirby JD; Bolton AE
    Int Angiol; 1997 Dec; 16(4):250-4. PubMed ID: 9543222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Thermography in evaluating therapy in Raynaud's disease].
    Litmanovitch J; Shilo R; Chayen M
    Harefuah; 1972 Jun; 82(11):503-6. PubMed ID: 5068900
    [No Abstract]   [Full Text] [Related]  

  • 29. Intra-arterial reserpine for Raynaud's syndrome. Systemic reactions without therapeutic benefit.
    Surwit RS; Gilgor RS; Duvic M; Allen LM; Neal JA
    Arch Dermatol; 1983 Sep; 119(9):733-5. PubMed ID: 6614959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Multivariate analysis as a method of determination of anthropogenic load on the course of Raynaud's disease in patients with systemic scleroderma and systemic lupus erythematosus].
    Kuchma GB; Bagirova VV; Setko NP
    Ter Arkh; 2001; 73(5):37-9. PubMed ID: 11517745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Thermographic assessment of Raynaud's phenomenon in childhood mixed connective tissue disease].
    Yokota S; Kuriyama T; Takahashi Y; Mori M; Shike H; Ibe M; Mitsuda T; Aihara Y
    Ryumachi; 1994 Dec; 34(6):955-60. PubMed ID: 7863385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome.
    Kahan A; Weber S; Amor B; Menkes CJ
    Lancet; 1983 Mar; 1(8323):538. PubMed ID: 6131248
    [No Abstract]   [Full Text] [Related]  

  • 33. [Therapeutic use of prostacyclin in cardiovascular pathology].
    Martelli M; Nicolosi G
    Minerva Med; 1983 Nov; 74(44):2665-70. PubMed ID: 6419178
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
    Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
    Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of Raynaud's phenomenon.
    García-Carrasco M; Jiménez-Hernández M; Escárcega RO; Mendoza-Pinto C; Pardo-Santos R; Levy R; Maldonado CG; Chávez GP; Cervera R
    Autoimmun Rev; 2008 Oct; 8(1):62-8. PubMed ID: 18692160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Calcium antagonists and Raynaud's phenomenon].
    Hachulla E; Devulder B
    Therapie; 1993; 48 Spec No():707-11. PubMed ID: 8091357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R; Shariat K; von Wilmowsky H; Böhm M
    Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Controlled multicenter double blind trial of an oral analog of prostacyclin in the treatment of primary Raynaud's phenomenon. French Microcirculation Society Multicentre Group for the Study of Vascular Acrosyndromes.
    Vayssairat M
    J Rheumatol; 1996 Nov; 23(11):1917-20. PubMed ID: 8923366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effect of a-sympathicolysis in Raynaud's syndrome].
    Westermann KW; Langbehn A; Feige A; Priester G
    Verh Dtsch Ges Inn Med; 1973; 79():1395-7. PubMed ID: 4275201
    [No Abstract]   [Full Text] [Related]  

  • 40. New prospects for the treatment of Raynaud's phenomenon using a serotoninergic S2 receptor antagonist (ketanserin) and stable derivatives of prostacyclin.
    Pola P; Tondi P; Serricchio M; Favuzzi A; Gerardino L
    Angiology; 1993 Feb; 44(2):123-8. PubMed ID: 8434805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.